pirenzepine has been researched along with Hypertriglyceridemia in 7 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
Hypertriglyceridemia: A condition of elevated levels of TRIGLYCERIDES in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Olanzapine is an atypical antipsychotic that is becoming more widely used in children and adolescents." | 5.31 | Hyperglycemia and hypertriglyceridemia secondary to olanzapine. ( Domon, SE; Webber, JC, 2001) |
| " A small number of reports documenting modest hypertriglyceridemia related to newer antipsychotics have implicated fluperlapine, clozapine, and, most recently, olanzapine." | 3.71 | Novel antipsychotics and severe hyperlipidemia. ( Meyer, JM, 2001) |
| "Olanzapine is an atypical antipsychotic that is becoming more widely used in children and adolescents." | 1.31 | Hyperglycemia and hypertriglyceridemia secondary to olanzapine. ( Domon, SE; Webber, JC, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stoner, SC | 1 |
| Dubisar, BM | 1 |
| Khan, R | 1 |
| Farrar, CD | 1 |
| Wetterling, T | 1 |
| Sheitman, BB | 1 |
| Bird, PM | 1 |
| Binz, W | 1 |
| Akinli, L | 1 |
| Sanchez, C | 1 |
| Osser, DN | 1 |
| Najarian, DM | 1 |
| Dufresne, RL | 1 |
| Nguyen, M | 1 |
| Murphy, T | 1 |
| Meyer, JM | 1 |
| Domon, SE | 1 |
| Webber, JC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Placebo-Controlled, Cross-Over Trial of Aripiprazole Added to Obese Olanzapine-Treated Patients With Schizophrenia[NCT00351936] | Phase 4 | 16 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Evaluating change in Body Mass Index (BMI) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | kg/m^2 (Mean) |
|---|---|
| Aripiprazole | -0.4 |
| Placebo | 0.3 |
Evaluating change in fasting total cholesterol between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -3 |
| Placebo | 9 |
Evaluating change in high-density lipoprotein cholesterol (HDL-C) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | 0.4 |
| Placebo | 0.6 |
Evaluating change in low-density lipoprotein (LDL) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -0.2 |
| Placebo | 3.1 |
Evaluating change in triglyceride levels between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -51.7 |
| Placebo | 47.6 |
Evaluating change in waist-hip ratio (WHR) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | cm (Mean) |
|---|---|
| Aripiprazole | 0.0 |
| Placebo | 0.0 |
Evaluating change in weight (lbs) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | lbs (Mean) |
|---|---|
| Aripiprazole | -2.9 |
| Placebo | 2.1 |
1 review available for pirenzepine and Hypertriglyceridemia
| Article | Year |
|---|---|
[Type 2 diabetes and dyslipidemia. Side effects of "Atypical" neuroleptics?].
Topics: Antipsychotic Agents; Benzodiazepines; Body Weight; Clozapine; Diabetes Mellitus, Type 2; Humans; Hy | 2003 |
1 trial available for pirenzepine and Hypertriglyceridemia
| Article | Year |
|---|---|
Olanzapine increases weight and serum triglyceride levels.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Female; Hospitalizat | 1999 |
5 other studies available for pirenzepine and Hypertriglyceridemia
| Article | Year |
|---|---|
Severe hypertriglyceridemia associated with olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Hospitalization; Humans; Hypertriglyceridemia; Male; O | 2002 |
Olanzapine-induced elevation of plasma triglyceride levels.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Drug Administr | 1999 |
Olanzapine and hypertriglyceridemia.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Child; Humans; Hypertriglyceridemia; Male; | 2001 |
Novel antipsychotics and severe hyperlipidemia.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Humans; Hyperl | 2001 |
Hyperglycemia and hypertriglyceridemia secondary to olanzapine.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Humans; Hyperglycemia; Hypertriglyceridemia; Male | 2001 |